Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy

Leukemia and Lymphoma

Volumn 53, Issue 10, 2012, Pages 1945-1948

  Rozman, Samo ^a   Sonc, Monika ^a   Novakovic, Barbara Jezersek ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Late onset neutropenia; Lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; CONTROLLED STUDY; HUMAN; INCIDENCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; INCIDENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEUTROPENIA; PREDNISONE; RETROSPECTIVE STUDIES; VINCRISTINE; YOUNG ADULT;

EID: 84865710176     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.679266     Document Type: Article

References (29)

1. ], Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106: 795-802.
2. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy-rare but there. Leuk Lymphoma 2009;50:1083-1095.
3. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 2003;30:3-8.
4. Molina A. Adecade of rituximab: improving survival outcomes in non-Hodgkin ' s lymphoma. Annu Rev Med 2008;59:237-250.
5. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535.
6. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br JHaematol 2003;121:913-918.
7. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br JDermatol 2007;157:1271-1273.
8. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47:1013-1017.
9. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. NEngl JMed 2003;348:2691-2694.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. JClin Oncol 1999;17:1244-1253.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. JClin Oncol 2007;25:579-586.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. 14 June 2010 [Internet]. Available from: http://ctep.cancer.gov/ default.htm
13. Nitta E, Izutsu K, Sato T, et al. Ahigh incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma:s singleinstitution study. Ann Oncol 2007;18:364-369.
14. McLaughlin P. Late-onset neutropenia following rituximab. Leuk Lymphoma 2006;47:965-966.
15. Fukuno K, Tsurumi H, Ando N, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin ' s lymphoma. Int JHematol 2006;84:242-247.
16. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin ' s lymphoma. Bone Marrow Transplant 2004;33:921-923.
17. Lai GG, Lim ST, Tao M, et al. Late-onset neutropenia following RCHOPchemotherapy in diffuse large B-cell lymphoma. Am JHematol 2009;84:414-417.
18. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor Fc RIIIa 158(V/F) polymorphism. Am JHematol 2010;85: 810-812.
19. Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008;25: 374-379.
20. Cairoli R, Grillo G, Tedeschi A, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004;89:361-363.
21. Institute of Oncology Ljubljana. Smernice za obravnavo bolnikov z malignimi limfomi. January 2011 [Internet]. Available from: http://www.onko-i. si/uploads/media/Doktrina-2011.pdf
22. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced lateonset neutropenia a good prognostic indicator in lymphoproliferative disorders? Br JHaematol 2011;153:411-413.
23. Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximabtreated lymphoma patients: report of two cases. Leuk Res 2002;26: 597-600.
24. Coakley G, Iqbal M, Brooks D, et al. CD8+, CD57+Tcells from healthy elderly subjects suppress neutrophil development in vitro: implication of Felty ' s and large granular lymphocyte syndromes. Arthritis Rheum 2000;43:834-843.
25. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with Blymphocyte depletion and infections. Arthritis Rheum 2011;63: 2209-2214.
26. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 2007;92:20-23.
27. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates Bcell growth. JExp Med 1999;189:1747-1756.
28. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/Fpolymorphisms influences the binding of IgGby natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/Hphenotype. Blood 1997;90:1109-1114.
29. Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3a-158Valleles predispose to late onset neutropenia after CHOP-Rfor diffuse large B-cell lymphoma. Intern Med J2011 Sep 1. [Epub ahead of print]